We Work for Health Virginia

05/21/2026

Thank you, Governor Abigail Spanberger for vetoing the Prescription Drug Affordability Board legislation (HB 483/SB 271) and standing up for patients, innovation, and access to life-saving treatments in Virginia.

This legislation would have created uncertainty for healthcare stakeholders and risked limiting access to new medicines for Virginians who need them most.

We appreciate Governor Spanberger’s leadership and commitment to policies that protect patient access and support continued medical innovation.

05/07/2026

Latino communities face disproportionate health challenges and Washington’s latest healthcare proposals risk making that worse — increasing delays, restricting access to treatments, and limiting future innovation. Real reform should lower costs by increasing transparency, holding insurers and PBMs accountable, and putting patients first. Find out more here:

The latest push in Washington to lower healthcare costs is overlooking the needs of those with the most at stake: Latino patients.Latino communities carry some of the highest rates of c

04/30/2026

We’re grateful to Senator Mark Warner for co-sponsoring the PBM Price Transparency and Accountability Act (S.3345), a meaningful step toward lowering costs and improving transparency for patients.

Pharmacy benefit managers play a major role in determining what patients pay and what treatments they can access. Bringing more accountability to that process helps ensure the system works as intended.

Read more here:

PBM reform championed by Sen. Warner is a necessary step to lower health care costs for patients, VA Bio’s John Newby writes in a guest column

04/21/2026

VAHO applauds Governor Abigail Spanberger's amendments to SB 271/HB 483, taking an important step to protect cancer patients’ access to care.

By requiring further study and a 2027 vote before certain drug pricing provisions take effect, these changes ensure policies won’t unintentionally disrupt treatment in communities across the Commonwealth.

Cancer patients need solutions that lower costs without risking access. VAHO urges the General Assembly to support these patient-focused amendments.

04/14/2026

Thank you, Governor Abigail Spanberger for taking a smart and measured approach to the PDAP legislation, SB271/ HB 483, which would have established a Prescription Drug Affordability Panel.

By requiring the Maximum Fair Price provisions to be re-enacted in 2027, this amendment stops a flawed policy from taking effect now and sends a clear signal that Virginia should not rush into government price-setting schemes that could undermine patient access and medical innovation.

This is a major win for patients, for innovation, and for a stronger life sciences future in the Commonwealth.

04/12/2026

Here's another perspective on how America can thrive in this competitive global economy.

A burdensome regulatory environment is pushing clinical trials overseas.

04/10/2026

Interesting article about our growing dependence on China and what we need to do about it.

The United States is increasingly reliant on China for pharmaceuticals, with the potential for the Chinese Communist Party to gain control of the global supply chain, posing a national security ris…

04/02/2026

Virginia leaders are right to focus on lowering the cost of prescription drugs, but the so-called “Affordable Medicine Act” may do more harm than good.

By importing federal price caps into state-regulated plans, this legislation risks limiting access to medications. Especially in rural communities where pharmacies are already struggling to stay open.

This approach could send the wrong signal to Virginia’s growing biotech sector, putting jobs, innovation, and future investment at risk.

We all share the goal of making medicine more affordable. Sustainable solutions start with transparency and addressing the real drivers of cost. Read more here:

Virginia’s so‑called Affordable Medicine Act, which would impose government‑mandated drug price caps tied to federal rules, threatens patient access to medications, rural pharmacies and the state’s growing biotech economy while

03/26/2026

Congressman Morgan Griffith gets it.

The 340B drug pricing program was built to help safety net providers serve low-income and vulnerable patients — a worthy mission. But as Rep. Griffith recently put it, the program "has become opaque, and a few hospitals have gone against the true intent of that good program."

He's right. When visibility into how discounts are used disappears, patients pay the price — literally. As Griffith noted, Americans are left "navigating complex and often expensive medical bills... bills that they did not anticipate, cannot easily afford, and sometimes only learn about weeks or months after receiving care."

Reform isn't about attacking 340B. It's about restoring the program's original purpose: getting savings to the patients who need them most. Glad to see leaders like Rep. Griffith willing to say so out loud.

The Committee on Energy and Commerce is the oldest standing legislative committee in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee.

03/19/2026

U.S.–Japan trade talks are a chance to fix a major imbalance:

Japan benefits from American medical innovation while keeping drug prices artificially low, shifting costs to U.S. patients & slowing R&D.

Trade policy should ensure allies pay their fair share to support future breakthroughs. Read more here:

Japanese Prime Minister Sanae Takaichi will arrive in Washington this week to meet with President Trump for trade discussions most policymakers anticipate will further bolster our two nations’ h

03/11/2026

Virginia is lucky to have U.S. Senator Tim Kaine working diligently on a federal fix for this federal program. Transparency and accountability will make this a true safety net program, just as it was intended!

Virginia hospitals are exploiting the 340B drug discount program to boost profits instead of helping low‑income patients as intended.